Another study (MONARCH 2 and 3, ClinicalTrials.gov ID: NCT02107703 and NCT02246621, respectively) dealt with a combination of abemaciclib with other active compounds (fulvestrant and non-steroidal aromatase inhibitors) in breast cancer. Here, CYP19A1 is linked to breast carcinoma.